FDA Priority Review Signals Potential Breakthrough for Limb-Girdle Muscular Dystrophy
As reported on BioSpace, the U.S. Food and Drug Administration (FDA) has granted priority review to BridgeBio Pharma’s investigational therapy, BBP-418, marking a key regulatory milestone for a condition that…